```html

Wyburn‑Mason Syndrome – Kompletny Przewodnik Medyczny

Overview

Wyburn‑Mason syndrome (WMS), also known as racemosa or arteriovenous malformation (AVM) of the brain‑eye, is a rare, non‑hereditary vascular disorder characterized by a complex network of arteriovenous malformations that involve the retina, optic nerve, and the brain (most often the thalamus, basal ganglia, or brainstem). Because the abnormal vessels are high‑flow, they can cause visual disturbances, neurological deficits, and, in severe cases, life‑threatening hemorrhage.

• Who it affects: Typically diagnosed in children or young adults (median age ≈ 12–30 years). Both sexes are affected equally.
• Prevalence: Fewer than 150 cases have been reported in the medical literature worldwide, making it an ultra‑rare condition (< 1 per 1 000 000 population).
• Geography: No clear geographic clustering; cases are reported globally.

Symptoms

Because WMS can involve ocular and cerebral structures simultaneously, symptoms are highly variable. The following list includes the most commonly reported manifestations, grouped by the anatomic site involved.

Ocular Symptoms

• Decreased visual acuity: Blurry or foggy vision in one or both eyes.
• Strabismus (misalignment of the eyes): Often the first sign in children.
• Proptosis: Forward displacement of the eyeball due to retro‑orbital vascular congestion.
• Retinal AVMs: Dilated, tangled vessels visible on fundoscopy; may cause “sea‑fan” appearance.
• Hemorrhage into the vitreous or sub‑retinal space: Sudden loss of vision, floaters, or eye pain.

Neurological Symptoms

• Headache: Often persistent, sometimes throbbing.
• Seizures: Focal or generalized; may be the presenting symptom.
• Hemiparesis or hemiplegia: Weakness or paralysis on one side of the body when the contralateral basal ganglia or thalamus is involved.
• Speech or language disturbances: Dysarthria, aphasia, or difficulty finding words.
• Ataxia and coordination problems: Especially when the cerebellar pathways are affected.
• Vertigo or dizziness.
• Visual field defects: Homonymous hemianopia or quadrantanopia from thalamic involvement.

Systemic / Miscellaneous Symptoms

• Persistent fatigue (secondary to chronic anemia from occult bleeding).
• Head pressure or a sensation of “fullness” behind the eyes.

Causes and Risk Factors

WMS is considered a congenital vascular malformation rather than an acquired disease. The exact pathogenesis is not fully understood, but current evidence points to the following mechanisms:

• Somatic mutation in vascular development genes: Studies have identified low‑level mosaic mutations in RASA1 and EphB4, which regulate endothelial cell growth and arterial‑venous differentiation.
• Abnormal embryologic angiogenesis: Failure of the normal “pruning” of primitive vessels during the 4th–5th week of gestation can leave a persistent high‑flow arteriovenous channel.
• Non‑hereditary pattern: No consistent familial transmission has been documented, distinguishing WMS from hereditary hemorrhagic telangiectasia.

Risk Factors

• Being born with a sporadic somatic mutation (cannot be prevented).
• Male sex shows a slight, non‑significant trend in some series, but overall risk is equal.
• Associated congenital anomalies (e.g., facial hemangiomas) may raise suspicion, though they are not causative.

Diagnosis

Because the syndrome involves both the eye and the brain, a multidisciplinary approach (ophthalmology, neurology, neuroradiology) is essential.

Clinical Examination

• Comprehensive eye exam with dilated fundus photography to document retinal AVMs.
• Neurological exam focusing on motor strength, cranial nerves, coordination, and visual fields.

Imaging Studies

• Magnetic Resonance Imaging (MRI) with MR‑angiography: Gold standard for visualizing cerebral AVMs, flow dynamics, and any associated gliosis or hemorrhage.
• Computed Tomography Angiography (CTA): Useful in emergency settings for rapid assessment of hemorrhage.
• Digital Subtraction Angiography (DSA): Invasive but provides the most detailed vascular map; essential for planning endovascular treatment.
• Fluorescein Angiography (FA) of the retina: Highlights retinal AVM architecture, leakage, and areas of non‑perfusion.

Laboratory Tests

Routine labs are usually normal, but a complete blood count (CBC) may reveal anemia if chronic retinal bleeding is present. Coagulation studies are done pre‑procedure if an intervention is planned.

Diagnostic Criteria (Proposed)

1. Presence of at least one retinal arteriovenous malformation confirmed by FA.
2. Concurrent intracranial AVM (clinical or radiologic evidence).
3. Absence of other systemic vascular disorders (e.g., hereditary hemorrhagic telangiectasia).

Treatment Options

There is no cure for WMS; therapy focuses on preventing complications, preserving vision, and reducing neurological morbidity. Treatment is individualized based on lesion size, symptoms, and patient age.

Observation

• Asymptomatic, small AVMs without hemorrhage may be monitored with annual MRI and ophthalmic examinations.

Endovascular Embolization

• First‑line for high‑flow cerebral AVMs that pose a hemorrhage risk.
• Uses detachable coils, liquid embolic agents (e.g., Onyx®), or particles to occlude feeder vessels.
• Success rates in case series range from 60‑80 % for symptom control, with a 3‑5 % risk of ischemic stroke.

Stereotactic Radiosurgery (SRS)

• Gamma Knife or CyberKnife delivers focused radiation to shrink AVM over 2‑4 years.
• Ideal for deep‑seated lesions not amenable to surgery.
• Obliteration rates approximate 70 % in published cohorts (Mayo Clinic, 2020).

Microsurgical Resection

• Reserved for AVMs causing compressive symptoms or those that have bled.
• Requires high‑skill neurosurgical centers; peri‑operative morbidity can be 10‑15 %.

Ophthalmic Interventions

• Laser photocoagulation: Useful for peripheral retinal AVMs with leakage.
• Vitrectomy: Indicated when vitreous hemorrhage severely impairs vision.
• Enucleation: Rare, performed only for painful, blind eyes with uncontrolled neovascularization.

Medical Management

• Antiepileptic drugs (AEDs): For seizure control (e.g., levetiracetam, lamotrigine).
• Blood pressure optimization: Hypertension can increase rupture risk; target <140/90 mmHg.
• Analgesics and anti‑inflammatory agents: For headache management.

Supportive / Lifestyle Measures

• Smoking cessation – smoking accelerates vascular fragility.
• Avoidance of high‑altitude activities or extreme Valsalva maneuvers (heavy lifting, straining) that may raise intracranial pressure.

Living with Wyburn‑Mason Syndrome

Although the condition is chronic, many patients lead active lives with appropriate monitoring and treatment.

Regular Follow‑Up Schedule

• Every 6–12 months: MRI/MRA and ophthalmic exam (more frequent if recent treatment).
• Yearly: Full neurological assessment and visual field testing.

Visual Aids & Rehabilitation

• Low‑vision devices (e.g., magnifiers, electronic reading aids) can compensate for reduced acuity.
• Occupational therapy for hand‑eye coordination if visual field loss is present.

Neuro‑cognitive Support

• Neuropsychological testing after any major bleed or intervention.
• Memory aids, structured routines, and stress‑reduction techniques.

Psychological Well‑Being

• Join rare‑disease support groups (e.g., RareConnect, local ophthalmology/neurology patient organizations).
• Consider counseling to address anxiety related to visual loss or stroke risk.

Practical Tips

• Carry an emergency card listing diagnosis, current medications, and contact information for treating physicians.
• Avoid contact sports or activities with high risk of head trauma.
• Maintain a healthy weight and balanced diet rich in omega‑3 fatty acids, which support vascular health.

Prevention

Because WMS is congenital and non‑heritable, primary prevention is not possible. However, secondary prevention—reducing the chance of complications—includes:

• Strict control of blood pressure and cholesterol.
• Smoking cessation and avoidance of illicit drugs (especially cocaine, which spikes blood pressure).
• Prompt treatment of any head injury or ocular trauma.
• Adherence to follow‑up appointments to detect lesion progression early.

Complications

If left untreated or inadequately monitored, WMS can lead to serious outcomes.

• Intracranial hemorrhage: Acute bleed carries a mortality of 20‑30 % and may cause permanent neurologic deficit.
• Progressive visual loss: Persistent retinal AVM leakage can lead to retinal detachment or irreversible blindness.
• Epilepsy: Chronic seizures may become refractory to medication.
• Stroke‑like episodes: Ischemia from AVM steal phenomenon.
• Secondary glaucoma: Due to elevated episcleral venous pressure from orbital AVMs.
• Psychosocial impact: Depression, anxiety, and reduced quality of life should be addressed early.

When to Seek Emergency Care

---

**Sources:** Mayo Clinic, National Institutes of Health (NIH) – Genetics Home Reference, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) Vascular Anomalies Guidelines, Cleveland Clinic, “Arteriovenous Malformations of the Retina and Brain” – *Journal of Neuro‑Ophthalmology* 2021, and recent case‑series reviews (2020‑2023).

```